Results 61 to 70 of about 17,802 (177)

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

Drugs in R&D, 2020
Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases.
Pablo Bascuñana, Luisa Möhle, Mirjam Brackhan, Jens Pahnke   +3 more
doaj   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

British Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang, Hio Lam Ho, F. David Horgen, Andrea Fleig, Zhong‐Ping Feng, Hong‐Shuo Sun   +5 more
wiley   +1 more source

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population

ARYA Atherosclerosis, 2017
BACKGROUND: Fingolimod (FTY-720) has shown efficacy in relapsing multiple sclerosis (MS), while some side effects of this drug have been recognized that the most important is cardiovascular side effects.
Morteza Abdar, Payam Ebrahimifar, Masoud Etemadifar   +2 more
doaj  

Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study

Iranian Journal of Allergy, Asthma and Immunology, 2018
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes. In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ and
Bahare Laribi, Mohammad Ali Sahraian, Mehdi Shekarabi, Rahimeh Emamnejad, Mohsen Marzban, Shokufeh Sadaghiani, Maryam Izad   +6 more
doaj   +1 more source

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

PLoS ONE, 2021
ObjectiveTo describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.MethodsAn observational ...
J E Meca-Lallana, C Oreja-Guevara, D Muñoz, J Olascoaga, A Pato, L Ramió-Torrentà, V Meca-Lallana, M A Hernández, M E Marzo, J C Álvarez-Cermeño, A Rodríguez-Antigüedad, X Montalbán, O Fernández, Spanish GILENYA Registry Investigators   +13 more
doaj   +1 more source

The effects of fingolimod and fingolimod-phosphate on BMECs.

, 2015
(A) The effects of fingolimod and fingolimod-phosphate on tight junction proteins, such as claudin-5 and occludin, and adhesion molecules, including ICAM-1 and MelCAM, in the human brain microvascular endothelial cells (BMECs) were measured using a ...
Fumitaka Shimizu (545145), Toshihiko Maeda (702834), Masaaki Abe (202786), Yasuteru Sano (545147), Michiaki Koga (60773), Takashi Kanda (545152), Yukio Takeshita (702833), Hideaki Nishihara (545149)   +7 more
core   +1 more source

Fingolimod Immune Effects Beyond Its Sequestration Ability [PDF]

, 2019
Fingolimod is the first orally administered drug approved for the treatment of relapsing-remitting multiple sclerosis (MS). This drug, modulating sphingosine receptors, regulates the trafficking of lymphocytes between primary and secondary lymphoid ...
Sica F., Centonze D., Buttari F.
core   +1 more source

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of patients with relapsing forms of multiple sclerosis (RMS).
Jeffrey A Cohen, Amit Bar-Or, Bruce A C Cree, Yang Mao-Draayer, May H Han, Barry Singer, Ann Jannu, Scott Kolodny, Xiangyi Meng, Ryan C Winger   +9 more
doaj   +1 more source

The Role of Innate Lymphoid Cells in Autoimmune, Allergic and Infectious Diseases: A Systematic Review

Immunology, EarlyView.
This systematic review establishes disease‐specific dysregulations of human innate lymphoid cells (ILCs), demonstrating that an ILC1/ILC3 imbalance compromises mucosal barriers in inflammatory bowel disease, while activated ILC2s drive allergic airway inflammation.
Luan F. Lückmann, Henrique R. Dal‐Pizzol, Louise M. Lückmann, Davi E. Salini, Bruna C. Hasckel, Mikaeli Minati, Bruno Kluwe‐Schiavon, Tatiana Barichello   +7 more
wiley   +1 more source